Researchers from McMaster University and MIT utilized generative artificial intelligence to discover enterololin, a narrow-spectrum antibiotic targeting Enterobacteriaceae associated with inflammatory bowel disease (IBD). This AI-driven approach accelerates identification of selective antimicrobial agents and represents a promising advance in combating high-priority pathogens involved in gut inflammation and disease management.